Figures (6)  Tables (2)
    • Figure 1. 

      Foveal adaptive optics (AO) imaging: quantitative comparison of cone photoreceptors. Adaptive optics (AO) imaging of the foveal center (right eye, 4° × 4° field of view). Yellow boxes denote five regions of interest (ROIs): temporal, nasal, superior, inferior (1.5° from foveal center), and superotemporal (0.5°). Red boxes highlight the superior ROI 2. Quantitative results (cone density, spacing, regularity, and distribution) are displayed for three groups (top to bottom): retinitis pigmentosa (RP) patients, RP carriers, and controls.

    • Figure 2. 

      Quantitative analysis of cone cell metrics in retinitis pigmentosa (RP) patients, carriers, and controls. (a) Cone density (cells/mm2) comparison. (b) Cone spacing (µm). (c) Regularity index (%). (d) Dispersion. Groups: RP (retinitis pigmentosa patients), carriers (RP carriers), ctrl (controls). Sample sizes: 49 control eyes, 19 carrier eyes, and 39 RP eyes. Statistical comparisons were performed using the Kruskal–Wallis test with Dunn's post-hoc test for pairwise comparisons. p < 0.05, * p < 0.01, *** p < 0.0001; ns, not significant.

    • Figure 3. 

      Percentage change in cone cell metrics relative to controls. Comparison of percentage changes in cone density, spacing, regularity, and dispersion between retinitis pigmentosa (RP) patients, RP carriers, and healthy controls (4° × 4° region). Data are expressed as mean % change from control values (baseline set at 0%).

    • Figure 4. 

      Multimodal partial correlations in retinitis pigmentosa (RP): AO, OCTA, and clinical metrics, adjusted for age, gender, and axial length. (a) AO-derived photoreceptor metrics (density, spacing, regularity, dispersion) vs clinical parameters (EZ length, LogMAR visual acuity). (b) OCTA-derived structural and vascular parameters vs clinical measures (EZ length, LogMAR visual acuity). (c) Cross-correlations between AO metrics and OCTA parameters. The color intensity indicates the strength of the correlation, with asterisks denoting statistical significance. Sample size: 39 RP eyes. Correlations were calculated using Spearman partial correlation analysis with adjustment for age, gender, and axial length. * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001. EZ, ellipsoid zone.

    • Figure 5. 

      Genotype–phenotype correlations in retinitis pigmentosa (RP) patients by AO/OCTA. Patients were stratified into four functional mutation groups: cilium, RNA-splicing, phototransduction, and metabolism-related. Inter-group comparisons were performed for choroidal thickness, total retinal blood-flow profile, photoreceptor density, dispersion, regularity, and spacing. Sample sizes: 16 genetically confirmed RP patients stratified into four functional mutation groups. The Kruskal–Wallis test was applied to non-normally distributed parameters; whenever the overall test was significant, Dunn's test was used for post-hoc pairwise comparisons. ** p < 0.01, * p < 0.05; ns, not significant.

    • Figure 6. 

      ROC analysis to distinguish asymptomatic retinitis pigmentosa (RP) carriers from controls. ROC curves show photoreceptor dispersion has the highest discriminative value among four AO-quantified metrics (dispersion, density, regularity, and spacing).

    • Patient no.Family no.GenderAgeGeneInheritanceGene-related mechanismsGenotypeMutations
      P1F1Male19USH2AARCiliumCompound heterozygoteNM_206933.2:c.99_100insT
      NM_206933.2:EX37-EX38 Dup
      P2F2Female62USH2AARCiliumCompound heterozygoteNM_206933.2:c.11156G>A
      NM_206933.2:c.13414G>A
      P3F3Male42USH2AARCiliumCompound heterozygoteNM_206933.2:c.11156G>A
      NM_206933.2:EX4-EX15 Del
      P4F4Male43USH2AARCiliumCompound heterozygoteNM_206933.2:c.11549-1G>A
      NM_206933.2:c.9958G>C
      P5F5Female67EYSARCiliumCompound heterozygoteNM_001142800.1:c.6416G>A
      NM_001142800.1:c.6385G>A
      P6F6Male39EYSARCiliumHomozygousNM_001142800.1:c.1798_1800delTTGinsC
      P7F7Female49SNRNP200ADRNA splicingHeterozygoteNM_014014.4:c.3260C>T
      P8F7Female25SNRNP200ADRNA splicingHeterozygoteNM_014014.4:c.3260C>T
      P9F8Male30RHOADPhototransductionHeterozygoteNM_000539.3:c.655_663delATCTTTTTC
      P10F9Female49IMPDH1ADMetabolismHeterozygoteNM_000883.3:c.174_183delGACGACACCC
      P11F10Female42RP1L1ARCiliumCompound heterozygoteNM_178857.5:c.4700G>A
      NM_178857.5:c.149G>A
      NM_178857.5:c.32C>T
      P12F11Male30RDH12ARMetabolismCompound heterozygoteNM_152443.2:c.437T>A
      NM_152443.2:c.193C>T
      P13F12Male28CNGB1ARPhototransductionCompound heterozygoteNM_001297.4:c.2284C>A
      NM_001297.4:c.2284C>T
      P14F13Male35CNGA1ARPhototransductionHomozygousNM_000087.3:c.1537G>A
      P15F14Male52CEP290ARCiliumCompound heterozygoteNM_025114.3: c.1666_1667insA NM_025114.3:c.503G>A
      P16F15Male37ALMS1ARCiliumCompound heterozygoteNM_001378454: c.812C>T
      NM_001378454: c.12163C>G
      P17F16Female30N/AN/AN/AN/AN/A
      P18F17Male46N/AN/AN/AN/AN/A
      P19F18Male46N/AN/AN/AN/AN/A
      P20F19Female29N/AN/AN/AN/AN/A
      P21F20Male40N/AN/AN/AN/AN/A
      P22F21Female9N/AN/AN/AN/AN/A
      AR: autosomal recessive, AD: autosomal dominant.

      Table 1. 

      Genotype and mutations' profiles in RP patients.

    • OCTAMean ± SD
      Inner retina thickness (µm)66.34 ± 32.27
      Outer retina thickness (µm)199.54 ± 66.28
      Central retina thickness (µm)273.13 ± 73.82
      Choroidal thickness (µm)255.43 ± 116.90
      Retinal blood flow superficial: ILM-IPL_fovea (%)21.12 ± 12.75
      Retinal blood flow deep: IPL-OPL_fovea (%)11.99 ± 12.68
      Retinal blood flow retina_fovea (%)20.33 ± 13.40
      FAZ superficial: ILM-IPL no flow area (mm2)0.9764 ± 1.7373
      FAZ deep: IPL-OPL no flow area (mm2)1.3357 ± 1.5496
      FAZ retina: ILM-OPL no flow area (mm2)1.1528 ± 1.8098
      Choroidal flow: (CVI, %)49.6429 ± 11.9667
      ILM, internal limiting membrane; IPL, inner plexiform layer; OPL, outer plexiform layer; FAZ, foveal avascular zone; CVI, choroidal vascularity index.

      Table 2. 

      OCTA parameters of RP patients.